IP Library Granted Patent US 8,449,611
Granted Patent B2
US 8,449,611 · App. 12/752,466 · Granted May 28, 2013

Intraocular lens

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,449,611
App. No.
12/752,466
Granted
May 28, 2013
Kind
B2
Abstract

An intraocular lens comprises an optic portion having a peripheral edge and at least two haptics. Each haptic is integrated with the peripheral edge of the optic portion by a corresponding haptic integration region. Also, each haptic comprises a distal segment region and a deformation segment region. The distal segment region has an outer distal length bounded by a proximate endpoint and a distal endpoint on an outer surface of the haptic, and is scribed by a distal segment angle α of 20° to 30°. The distal segment angle has a segment origin that lies within a radial segment bound by a radial distance 1.5 mm to 1.9 mm from an optic center and a segment angle θ of from 30° to 45° from a vertical axis. The vertical axis extends through the distal endpoint of at least one haptic and the optic center.

Claims (31)

1. An intraocular lens comprising an optic portion having a peripheral edge and at least two haptics, each haptic integrated with the peripheral edge of the optic portion by a corresponding haptic integration region, each haptic comprising a distal segment region and a deformation segment region,

wherein the distal segment region has an outer distal length defined by a proximate endpoint and a distal endpoint on an outer surface of the haptic, the distal segment region scribed by a distal segment angle α of 200 to 300, and the outer surface of the distal segment region is arcuate with a radius of curvature of 4.3 mm to 5.7 mm, and

the deformation segment region has an outer deformation length bounded by a proximate deformation endpoint on an outer surface of the haptic and the proximate endpoint of the distal segment region, the deformation segment region scribed by a deformation segment angle β of 20° to 40°,

the distal segment angle and the deformation segment angle having a segment origin that lies within a radial segment bound by a radial distance 1.5 mm and 1.9 mm from an optic center and a segment angle θ of from 30° and 45° from a vertical axis, the vertical axis extending through the distal endpoint of at least one haptic and the optic center,

wherein a portion of the outer surface of the distal segment region and a portion of the outer surface of the deformation segment region combine to form an angle of contact of not less than 52° and not more than 70° with an arcuate jaw if the haptics are concentrically stressed to a jaw diameter of 10 mm in accordance with ISO Test No. 11979-3(2006).

2. The intraocular lens of claim 1 wherein at least 80% of the distal segment region and at least 70% of the deformation segment region have a constant width W H of from 0.25 mm to 0.65 mm.

3. The intraocular lens of claim 1 wherein the integration region comprises an opening thereby forming outer and inner integration members.

4. The intraocular lens of claim 1 wherein the distal segment angle is from 22° to 28°, and the segment origin extends the radial distance 1.6 mm to 1.8 mm from the optic center.

5. The intraocular lens of claim 1 wherein the radial segment is bound by a radial distance of 1.62 mm to 1.72 mm from the optic center, and the segment angle θ of 34° to 40° from the vertical axis.

6. The intraocular lens of claim 1 wherein a portion of the outer surface of the distal segment region and a portion of the outer surface of the deformation segment region combine to form an angle of contact of not less than 50° with a lenticular capsular bag of a human eye when the haptics are stressed following implantation of the lens into the bag.

7. The intraocular lens of claim 1 wherein the segment origin translates to an implanted radial distance of 0.3 mm or less from the optic center when the haptics are stressed following implantation of the lens into a lenticular capsular bag of a human eye.

8. The intraocular lens of claim 1 wherein the segment origin translates to an implanted radial distance of 0.3 mm or less from the optic center if the haptics are concentrically stressed in a model representation of a lenticular capsular bag of a human eye in accordance with ISO Test No. 11979-3(2006).

9. The intraocular lens of claim 1 formed as a one-piece, polymeric material with a tangent modulus of elasticity of from 2 MPa to 6 MPa.

10. The intraocular lens of claim 1 wherein the optic portion comprises an anterior face and a substantially opposing posterior face, wherein the anterior face includes a central face, a peripheral face and an annular face, the annular face posteriorly recessed between the central face and the peripheral face.

11. A one-piece intraocular lens comprising an optic portion and two haptics, each haptic integrated to a peripheral edge of the optic portion by a haptic integration region, and the optic portion, the two haptics and the haptic integration regions each comprise a polymeric material having a tangent modulus of elasticity of from 2 MPa to 6 MPa, wherein

each of the haptics comprise a distal segment region and a deformation segment region, wherein the distal segment region has an outer distal length bounded by a proximate and a distal endpoint on an outer surface of the haptic, the distal segment region scribed by a distal segment angle α of 20° to 30°, the distal segment angle having a segment origin that lies within a radial segment bound by a radial distance of 1.5 mm and 1.9 mm from an optic center and a segment angle θ of 34° and 40° from a vertical axis, the vertical axis extending through the distal endpoint of at least one of the two haptics and the optic center, and

each of the deformation segment regions has an outer deformation length bounded by a proximate deformation endpoint on an outer surface and the proximate endpoint of the corresponding distal segment region, the deformation segment region scribed by a deformation segment angle β of 20° to 40° from the segment origin, and

a portion of the outer surface of the distal segment region and a portion of the outer surface of the deformation segment region combine to form an angle of contact of not less than 52° and not more than 70° with an arcuate jaw, and the segment origin translates to a point within 0.3 mm or less of a radial distance from the optic center, if the haptics are concentrically stressed to a jaw diameter of 10 mm in accordance with ISO Test No. 11979-3(2006).

12. The intraocular lens of claim 11 wherein the distal segment angle α is from 22.5° to 27.5°, the segment origin extends 1.6 mm to 1.8 mm radially from the optic center, and the outer surface of the distal segment region is arcuate with a radius of curvature of 4.6 mm to 5.4 mm.

13. The intraocular lens of claim 11 wherein corresponding portions of the outer surfaces of the distal segment region and deformation segment region combine to form an angle of contact of not less than 52° and not more than 70° with a lenticular capsular bag of a human eye when the haptics are stressed following implantation of the lens into the bag.

14. The intraocular lens of claim 11 wherein the optic portion has a refractive power of 19 diopters to 22 diopters, an optic center thickness of 0.50 mm to 0.60 mm and a nominal cross-sectional area of 2.1 mm 2 to 2.7 mm 2 .

15. A one-piece intraocular lens comprising an optic portion with an optic center and at least two haptics, each haptic integrated to a peripheral edge of the optic portion by a haptic integration region, and each of the haptics comprise a distal segment region ending with a distal endpoint on an outer surface of the haptic and a deformation segment region beginning with a proximate deformation endpoint on the outer surface of the haptic, wherein the distal endpoint and the proximate deformation segment endpoint are further defined by a sum of a distant segment angle α and a deformation segment angle β and a segment origin that is 1.5 mm and 1.9 mm from the optic center if the intraocular lens is unstressed,

wherein upon applying a concentric stress to the intraocular lens with an arcuate jaw to a diameter of 10 mm in accordance with ISO Test No. 11979-3(2006) a portion of the distal segment region and a portion of the deformation segment region combine to form an angle of continuous contact of not less than 52° and not more than 70° with the arcuate jaw, and the segment origin translates to an implanted radial distance of 0.3 mm or less from the optic center.

16. The intraocular lens of claim 15 wherein the optic portion comprises an anterior face and a substantially opposing posterior face, wherein the anterior face includes a central face, a peripheral face and an annular face, the annular face posteriorly recessed between the central face and the peripheral face.

17. The intraocular lens of claim 15 wherein the optic portion and the at least two haptics comprises of a polymeric material with a tangent modulus of elasticity of from 2 MPa to 6 MPa.

18. The intraocular lens of claim 16 wherein the optic portion has a refractive power of 19 diopters to 22 diopters, an optic center thickness of 0.50 mm to 0.60 mm and a nominal cross-sectional area of 2.1 mm 2 to 2.7 mm 2 .

19. The intraocular lens of claim 1 wherein the outer surface of the deformation segment region is arcuate with a radius of curvature of 4.3 mm to 5.7 mm.

20. The intraocular lens of claim 1 wherein the distal segment angle is from 24° to 26°, and the segment origin extends the radial distance 1.65 mm to 1.72 mm from the optic center.

21. The intraocular lens of claim 15 wherein the radial segment is bound by the radial distance of 1.6 mm to 1.8 mm from the optic center, and the segment angle θ of 33° to 40° from the vertical axis.

22. The intraocular lens of claim 1 wherein the radial segment is bound by the radial distance of 1.62 mm to 1.74 mm from the optic center, and the segment angle θ of 34° to 39° from the vertical axis.

23. The intraocular lens of claim 15 wherein the radial segment in the unstressed lens is bound by the radial distance of 1.6 mm to 1.8 mm from the optic center.

Assignments (28)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (059913/0548) Recorded Aug 14, 2025
From: CITIBANK, N.A., AS RESIGNING AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 072469/0091 →
PATENT SECURITY AGREEMENT Recorded Jul 1, 2025
From: BAUSCH & LOMB INCORPORATED; ALDEN OPTICAL LABORATORIES, INC.; BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 071773/0871 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
PATENT SECURITY AGREEMENT Recorded Oct 4, 2023
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 065120/0086 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 048556/0758) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH COMPANIES INC.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0484 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 056811/0814) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061872/0669 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 059121/0001) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061873/0001 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 043251/0932) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH
Reel/Frame 061872/0099 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 039380/0385) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061775/0128 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
PATENT SECURITY AGREEMENT Recorded May 10, 2022
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK, N.A. AS COLLATERAL AGENT
Reel/Frame 059913/0548 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
SECURITY INTEREST Recorded Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Jul 19, 2017
From: BAUSCH & LOMB INCORPORATED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0932 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2012
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028726/0142 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2010
From: RICHARDSON, GARY A.
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 024427/0616 →
SECURITY AGREEMENT Recorded May 13, 2010
From: WP PRISM INC.; BAUSCH & LOMB INCORPORATED; B&L CRL, INC.; B&L CRL PARTNERS, L.P.; B & L DOMESTIC HOLDINGS CORP.; B&L FINANCIAL HOLDINGS CORP.; B&L SPAF INC.; B&L VPLEX HOLDINGS, INC.; BAUSCH & LOMB CHINA, INC.; BAUSCH & LOMB INTERNATIONAL, INC.; BAUSCH & LOMB REALTY CORPORATION; BAUSCH & LOMB SOUTH ASIA, INC.; BAUSCH & LOMB TECHNOLOGY CORPORATION; IOLAB CORPORATION; RHC HOLDINGS, INC.; SIGHT SAVERS, INC.; WILMINGTON MANAGEMENT CORP.; WILMINGTON PARTNERS L.P.; B&L MINORITY DUTCH HOLDINGS LLC; EYEONICS, INC.
To: CREDIT SUISSE AG
Reel/Frame 024380/0286 →